01—Abstract
Summary
Summary of the 10-K filed March 14, 2008. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (filed under this name; now HALO on NASDAQ) reported total revenues of $3,799,521a for fiscal 2007, up from $981,746 in 2006, while net loss widened to $23,896,183 ($0.32 per share) from $14,751,986 ($0.24 per share).
Revenue under collaborative agreements was $3,159,931b and product sales were $639,590. Research and development expense rose to $20,554,105 from $9,214,759, and selling, general and administrative expense rose to $11,155,194 from $6,912,853, reflecting outsourced pre-clinical work, rHuPH20 manufacturing scale-up, and headcount growth. The company stated its accumulated deficit was approximately $65.0 million at December 31, 2007, and that it has never been profitable.
Cash and cash equivalents increased to $97,679,085c at year-end 2007 from $44,189,403, driven by financing of $56,002,668, including approximately $32.1 million from a sale of common stock to New River Management V, LP, approximately $20.0 million from an affiliate of Baxter, and $21.0 million of initial upfront payments from Baxter. Deferred revenue rose to $39,269,491. The company stated its current cash should be sufficient for at least the next twelve months and anticipated 2008 cash expenses of approximately $40 million to $50 million.
It also disclosed warrants to purchase about 4.9 million shares outstanding, with a universal shelf registration allowing up to $32.5 milliond of additional securities. The business rests on its recombinant human PH20 hyaluronidase (rHuPH20) platform. Hylenex and Cumulase are marketed products, and Chemophase, its lead oncology candidate, is in Phase I/IIa.
Partnerships with Roche (up to thirteen targets, $20 million upfront) and Baxter (Enhanze and Gammagard agreements) are central to its revenue outlook. The filing identifies heavy dependence on a single contract manufacturer (Avid Bioservices) and on Baxter for Hylenex distribution and fill-finish as key risks.
02—Key points
Key Highlights
- Total revenues rose to $3,799,521 in 2007 from $981,746 in 2006, with collaborative agreement revenue of $3,159,931.
- Net loss increased to $23,896,183 ($0.32 per share) in 2007 from $14,751,986 ($0.24 per share) in 2006.
- Research and development expense was $20,554,105 in 2007 versus $9,214,759 in 2006; SG&A was $11,155,194 versus $6,912,853.
- Cash and cash equivalents were $97,679,085 at December 31, 2007, up from $44,189,403, and management expects current cash to fund operations for at least the next twelve months.
- Management anticipates 2008 cash expenses of approximately $40 million to $50 million.
- Roche agreement provides a $20 million upfront payment, with milestones potentially reaching $111 million and royalties on the first three targets; Baxter Gammagard License provides a $10 million upfront payment with $37 million in further milestones.
- Concentration and dependency risks: Baxter and Roche accounted for 36% and 50% of 2007 total revenues, and the company relies on a single third-party manufacturer for its active pharmaceutical ingredient.
03—Questions
Frequently Asked Questions
How much revenue did Halozyme generate and where did it come from?
Total revenues were $3,799,521 in 2007, of which $3,159,931 was revenue under collaborative agreements and $639,590 was product sales of Cumulase and the API for Hylenex. Revenue under collaborative agreements increased primarily from amortization of upfront fees from Baxter and Roche and reimbursements for research and development services.
Why did the net loss increase in 2007?
The filing attributes the increase in net loss to higher operating expenses, partially offset by higher revenues and interest income. Research and development expense rose to $20.6 million, driven by outsourced pre-clinical programs and manufacturing scale-up of rHuPH20, and selling, general and administrative expense rose to $11.2 million, driven largely by compensation costs.
Is the company's cash position sufficient for the near term?
Management believes current cash and cash equivalents of $97.7 million will be sufficient to fund operations for at least the next twelve months. It anticipates 2008 cash expenses of approximately $40 million to $50 million, and it may also raise funds through equity sales, callable warrant exercises, collaborations, or debt financing.
What are the main risks to the company's business?
The company has only minimal product revenue, a history of losses, and has never been profitable. It depends on regulatory approvals for product candidates, on partners such as Baxter and Roche, and on a sole contract manufacturer for its API. It also faces intense competition, and the filing notes that its products are priced at a premium to animal-derived alternatives, which may slow adoption.
What dilution or stock-related risks does the filing disclose?
Warrants to purchase approximately 4.9 million shares were outstanding, and about 1.6 million of these are callable at $1.75 per share. The company has a universal shelf registration allowing up to $32.5 million of additional equity or debt securities, and sales of these shares could dilute existing stockholders and pressure the stock price.
04—Continue